Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
ZoetisAbbVie
Last price
$73.08$272.42
Currency
USD
USD
$30B$480B
11.6776.66
$6.13$3.54
0.730.28
$2.09$6.83
2.96%2.55%
Sector
HealthHealth
Employees
14,50057,000
Ticker
$ZTS$ABBV
Primary listing
NYSENYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $ZTS or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.